Enarodustat was originated by JT and has been developed in
Enarodustat is an orally-active HIF-PH inhibitor that promotes erythropoiesis by accelerating the endogenous production of erythropoietin (EPO) and controlling the expression of molecules responsible for iron metabolism. The Phase 3 clinical studies confirmed efficacy in anemic patients with non-dialysis dependent CKD and dialysis dependent CKD. Furthermore, the favorable tolerability profile on safety of enarodustat was obtained during the studies. JT and Torii expect enarodustat to be a new therapeutic option for anemia associated with CKD in
ABOUT Anemia Associated with CKD
Anemia is one of the complications in CKD patients. The major cause of anemia in patients with CKD is considered to be a decreased ability to produce EPO in the kidney associated with renal dysfunction. Insufficient oxygen supply due to decreased erythrocyte counts associated with anemia decreases the energy production in organs and induces reduction in mobility and activities in daily life, which leads to a poor quality of life.
Contact:
Tel: +81-3-5572-4292
Email: jt.media.relations@jt.com
(C) 2019 Electronic News Publishing, source